trending Market Intelligence /marketintelligence/en/news-insights/trending/rv7ihlqb41ewelqqisilrq2 content esgSubNav
In This List

Sarepta signs investment, licensing deal with Lacerta for gene therapy programs

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Sarepta signs investment, licensing deal with Lacerta for gene therapy programs

Sarepta Therapeutics Inc. signed investment and licensing agreements with privately held Lacerta Therapeutics Inc. for multiple gene therapy programs.

Under the agreement, Sarepta will make a $30 million equity investment in Lacerta and get a license to up to three central nervous system-targeted gene therapy programs, including exclusive rights to the gene therapy candidate for the metabolic disorder Pompe disease and options to two additional candidates.

Cambridge, Mass.-based Sarepta said that the transaction will expand its gene therapy pipeline to up to 11 unique candidates.

Alachua, Fla.-based Lacerta will manage the majority of preclinical development, while Sarepta will lead clinical development and commercialization of the product candidates.

Sarepta will owe development and sales-based milestones to Lacerta, along with royalties on net sales.